170 related articles for article (PubMed ID: 38427078)
21. Integrated multiomic analysis reveals disulfidptosis subtypes in glioblastoma: implications for immunotherapy, targeted therapy, and chemotherapy.
Yang X; Cai Z; Wang C; Jiang C; Li J; Chen F; Li W
Front Immunol; 2024; 15():1362543. PubMed ID: 38504986
[TBL] [Abstract][Full Text] [Related]
22. Integrative analysis with machine learning identifies diagnostic and prognostic signatures in neuroblastoma based on differentially DNA methylated enhancers between INSS stage 4 and 4S neuroblastoma.
Li S; Mi T; Jin L; Liu Y; Zhang Z; Wang J; Wu X; Ren C; Wang Z; Kong X; Liu J; Luo J; He D
J Cancer Res Clin Oncol; 2024 Mar; 150(3):148. PubMed ID: 38512513
[TBL] [Abstract][Full Text] [Related]
23. Disulfidptosis-Associated lncRNAs are Potential Biomarkers for Predicting Immune Response and Prognosis Within Individuals Diagnosed with Hepatocellular Carcinoma.
Wei Q; Hou YC; Mao FF; Feng JK; Wang X; Cheng SQ
Hepat Med; 2023; 15():249-264. PubMed ID: 38162389
[TBL] [Abstract][Full Text] [Related]
24. Identification and validation of disulfidptosis-related gene signatures and their subtype in diabetic nephropathy.
Xu D; Jiang C; Xiao Y; Ding H
Front Genet; 2023; 14():1287613. PubMed ID: 38028597
[No Abstract] [Full Text] [Related]
25. Identification and validation of a disulfidptosis-related genes prognostic signature in lung adenocarcinoma.
Zhang Y; Sun J; Li M; Hou L; Wang Z; Dong H; Xu W; Jiang R; Geng Y; Guan C; Zhu Z; Wang H; Gong Q; Zhang G
Heliyon; 2024 Jan; 10(1):e23502. PubMed ID: 38223725
[TBL] [Abstract][Full Text] [Related]
26. Identifying disulfidptosis subtypes in hepatocellular carcinoma through machine learning and preliminary exploration of its connection with immunotherapy.
Chen G; Zhang G; Zhu Y; Wu A; Fang J; Yin Z; Chen H; Cao K
Cancer Cell Int; 2024 Jun; 24(1):194. PubMed ID: 38831301
[TBL] [Abstract][Full Text] [Related]
27. Machine learning methods revealed the roles of immune-metabolism related genes in immune infiltration, stemness, and prognosis of neuroblastoma.
Mu J; Gong J; Lin P; Zhang M; Wu K
Cancer Biomark; 2023; 38(2):241-259. PubMed ID: 37545226
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of a novel stemness-related prognostic model for neuroblastoma using integrated machine learning and bioinformatics analyses.
Xia Y; Wang C; Li X; Gao M; Hogg HDJ; Tunthanathip T; Hulsen T; Tian X; Zhao Q
Transl Pediatr; 2024 Jan; 13(1):91-109. PubMed ID: 38323183
[TBL] [Abstract][Full Text] [Related]
29. Identification a unique disulfidptosis classification regarding prognosis and immune landscapes in thyroid carcinoma and providing therapeutic strategies.
Feng Z; Zhao Q; Ding Y; Xu Y; Sun X; Chen Q; Zhang Y; Miao J; Zhu J
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11157-11170. PubMed ID: 37347261
[TBL] [Abstract][Full Text] [Related]
30. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
[TBL] [Abstract][Full Text] [Related]
31. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
Zhao S; Wang L; Ding W; Ye B; Cheng C; Shao J; Liu J; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1180404. PubMed ID: 37152941
[TBL] [Abstract][Full Text] [Related]
32. Identification of disulfidptosis related subtypes, characterization of tumor microenvironment infiltration, and development of DRG prognostic prediction model in RCC, in which
Xu K; Zhang Y; Yan Z; Wang Y; Li Y; Qiu Q; Du Y; Chen Z; Liu X
Front Immunol; 2023; 14():1205250. PubMed ID: 37426643
[TBL] [Abstract][Full Text] [Related]
33. Unraveling the role of disulfidptosis-related LncRNAs in colon cancer: a prognostic indicator for immunotherapy response, chemotherapy sensitivity, and insights into cell death mechanisms.
Chi H; Huang J; Yan Y; Jiang C; Zhang S; Chen H; Jiang L; Zhang J; Zhang Q; Yang G; Tian G
Front Mol Biosci; 2023; 10():1254232. PubMed ID: 37916187
[No Abstract] [Full Text] [Related]
34. Identification and validation of disulfidptosis-associated molecular clusters in non-alcoholic fatty liver disease.
Yu X; Guo Z; Fang Z; Yang K; Liu C; Dong Z; Liu C
Front Genet; 2023; 14():1251999. PubMed ID: 37745847
[No Abstract] [Full Text] [Related]
35. Establishment of a prognostic risk prediction model incorporating disulfidptosis-related lncRNA for patients with prostate cancer.
Mulati Y; Lai C; Luo J; Hu J; Xu X; Kong D; Xiao Y; Liu C; Xu K
BMC Cancer; 2024 Jan; 24(1):44. PubMed ID: 38191330
[TBL] [Abstract][Full Text] [Related]
36. Identification of disulfidptosis-related subtypes and development of a prognosis model based on stacking framework in renal clear cell carcinoma.
Peng K; Wang N; Liu Q; Wang L; Duan X; Xie G; Li J; Ding D
J Cancer Res Clin Oncol; 2023 Nov; 149(15):13793-13810. PubMed ID: 37530800
[TBL] [Abstract][Full Text] [Related]
37. Single-cell sequencing and bulk RNA data reveal the tumor microenvironment infiltration characteristics of disulfidptosis related genes in breast cancer.
Chen Y; Jin C; Cui J; Diao Y; Wang R; Xu R; Yao Z; Wu W; Li X
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12145-12164. PubMed ID: 37428249
[TBL] [Abstract][Full Text] [Related]
38. Disulfidptosis features and prognosis in head and neck squamous cell carcinoma patients: unveiling and validating the prognostic signature across cohorts.
Xue H; Sun Q; Zhang H; Huang H; Xue H
J Cancer Res Clin Oncol; 2024 Mar; 150(3):156. PubMed ID: 38526631
[TBL] [Abstract][Full Text] [Related]
39. Identification of
Shao F; Wang Z; Wang S
DNA Cell Biol; 2021 Feb; 40(2):332-347. PubMed ID: 33393844
[TBL] [Abstract][Full Text] [Related]
40. A novel cuproptosis-related subtypes and gene signature associates with immunophenotype and predicts prognosis accurately in neuroblastoma.
Tian XM; Xiang B; Yu YH; Li Q; Zhang ZX; Zhanghuang C; Jin LM; Wang JK; Mi T; Chen ML; Liu F; Wei GH
Front Immunol; 2022; 13():999849. PubMed ID: 36211401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
